Voyager Therapeutics (NASDAQ:VYGR) is a dynamic biotechnology firm engaged in developing gene therapies that aim to provide life-changing treatments for severe neurological diseases. This endeavor involves a focus on creating innovative viral vector platforms to deliver genetic material directly into cells to correct or counteract diseases like Parkinson's, Huntington's, and ALS, among others. By pushing the boundaries of gene therapy, Voyager Therapeutics seeks not only to expand scientific understanding but also to translate groundbreaking research into therapies that can profoundly impact patient care and quality of life. The company's objectives are deeply rooted in a commitment to innovation, patient health, and developing sustainable treatments that address some of the most challenging medical conditions faced today.